Log in to search using one of your social media accounts:

Lawsuit accuses DaVita of failing to pay overtime
A Wheat Ridge law firm has alleged in a collective-action lawsuit that DaVita Inc. has failed to pay overtime wages to employees working before and after their shifts ended. Ramos Law Firm also is looking to track down workers employed in other states by the Denver-based kidney-care company (NYSE: DVA) as potential plaintiffs. In the federal lawsuit, the law firm alleges that some DaVita workers have been required to put in time before and after shifts and have had t o come back early from lunch… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Ed Sealover Source Type: news

Legacy Health CEO Brown announces retirement
Dr. George Brown, who has led Portland ’s Legacy Health hospital system for the past nine years, announced that he will retire at the end of the year. Under Brown’s leadership as president and CEO of Legacy, the eight-hospital system has experienced record growth, expanded into health insurance and beefed up its urgent care. Brown o versaw the addition of Randall Children’s Hospital and collaborations with other Portland health systems to create the Unity Center for Behavioral Health and expanded… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news

​Avery Dennison buys Finesse Medical
Avery Dennison Corp. has acquired Finesse Medical Ltd., an Irish maker of materials used for wound care and skin treatments, as part of plans to expand in the medical sector. Financial terms of the deal weren’t disclosed. Longford, Ireland-based Finesse Medical specializes in the development and application of products such as skin barrier films and protection creams, and silicone and polyurethane foam wound dressings. Finesse, which also provides contract manufact uring and product development… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: I-Chun Chen Source Type: news

Moffitt expansion plan gains flexibility with land purchase
Moffitt Cancer Center has some additional options for its expansion plan, with the purchase of land across the street from its McKinley campus south of the University of South Florida. Moffitt paid $11.75 million to purchase the site, at 10901 Malcolm McKinley Drive, on April 10, according to Hillsborough County property records. Moffitt has no specific use in mind at this time for the land, said Jack Kolosky, chief operating officer of Moffitt Cancer Center and president of Mo ffitt Hospital. “What… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Margie Manning Source Type: news

One of Birmingham's most influential medical leaders retiring
One of the most influential executives in Birmingham's health care scene will retire later this year. Dr. Edward E. Partridge, who has served as the director of the University of Alabama at Birmingham Comprehensive Cancer Center since 2007, will be retiring from the position at the end of July. UAB is conducting a national search to find his successor. In addition to his current role, Partridge s erved as professor of obstetrics and gynecology at UAB, in addition to previously serving as director… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Ty West Source Type: news

All-ages planned community in Liberty aims to connect generations, COO says
After years of managing assisted living, Melissa O'Hara said the unique vision for a multigenerational neighborhood drew her to the Kansas City area. As the community's COO, O'Hara will oversee Norterre — a 17-acre neighborhood — that will open in the fall in Liberty. Norterre is the result of a partnership among Manhattan-based Action Pact Design Group, Liberty Hospital and Healthy Living Centers of America. O'Hara became familiar with th e project after meeting Action Pact CEO Steve Shields. "I… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news

Aussie duo find global consumers for Indian generics
This endeavour has turned out to be an underground startup of sorts that connects patients and doctors to generic drug suppliers in India, this gaining access to low-cost versions. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2017 Category: Pharmaceuticals Source Type: news

Shawnee Mission Health wraps up $23.5M hospital renovation
Shawnee Mission Medical Center capped a three-year renovation of its first floor with a new simulation center and conference center. The $23.5 million renovation of Shawnee Mission Health's original hospital tower was designed to help support the continued education of its physicians, nurses and associates. The new Zamierowski Simulation Center unites all of the hospital's training tools into one location, which allows for more immersive, multidisciplinary training for physicians, nurses and support… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news

Des Peres doctor to pay nearly $300,000 to settle false billing allegations
The federal government has reached a civil settlement with Dr. Sherry Ma and Aima Neurology, following alleged false Medicare billings related to Dr. Ma ’s Botox and Myobloc injections at the medical group, according to the U.S. Attorney’s Office for the Eastern District of Missouri. Dr. Ma, of Ladue, and Aima Neurology will repay the United States $291,288, according to the U.S. Attorney’s Office. According to the U.S. Attorney's Office, Dr . Ma received Botox and Myobloc at no charge to use… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Veneta Rizvic Source Type: news

Holliston biotech faces possible delisting, but CEO remains confident
Biostage, a Holliston-based biotech developing organ implants to treat cancers in the respiratory tract, said Monday it faces a possible delisting from the Nasdaq. But its CEO, a former top official at Genzyme, remains confident that the company will avoid that fate. Biostage (Nasdaq: BSTG) said Monday it had received a letter from the exchange stating that it failed to meet two minimum requirements for listing: a $1 share price and $2.5 million in stockholders' equity. The 25-employee company said… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Addictions program expansion will help the community, and Eastern Niagara's bottom line
Eastern Niagara Hospital ’s CEO says an expansion of its chemical dependency program is one part of a larger plan to shore up operations and strengthen the hospital system. With one final approval expected in early June by state health officials, the hospital will move its 20-bed inpatient addictions treatment program fr om Lockport and expand it to 30 beds at its Newfane site, where it previously operated a 63-bed inpatient hospital. Clare Haar, CEO, says the 30-year-old program provides a much-needed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Tracey Drury Source Type: news

Puma Biotech Shares Are Roaring On An FDA Review. Here's What Could Still Go Wrong
Puma's having a great day, with its stock up 35%. Is it time to pounce? Take a look at what could go wrong at the company's FDA hearing on Wednesday, first. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:PBYI Source Type: news

Smart insects put a fly in the gene-editing ointment
Optimism that research can outsmart disease-carriers hits a setback (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 22, 2017 Category: Pharmaceuticals Source Type: news

Medicare Monday: Did you know Medicare Part B uses a market-based system to pay for medicines?
We often discuss the creation ofPart D when we talk about the market-based changes that the Medicare Modernization Act (MMA) made to Medicare, but that ’s just one example. Today, let’s take a closer look at the market-based changes that the MMA made to Medicare Part B with the creation ofAverage Sales Price (ASP). (Source: The Catalyst)
Source: The Catalyst - May 22, 2017 Category: Pharmaceuticals Tags: Medicare Medicare Monday Part B Source Type: news

AstraZeneca sells Seloken European rights for $300m
Anglo-Swedish group to make and supply beta-blocker to Italian drugmaker Recordati (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 22, 2017 Category: Pharmaceuticals Source Type: news

Spero Therapeutics Appoints Joel Sendek as Chief Financial Officer
Carol Waldo Also Joins Leadership Team as Head of Regulatory Affairs CAMBRIDGE, Mass., May 22, 2017 -- (Healthcare Sales & Marketing Network) -- Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment o... Biopharmaceuticals, Personnel Spero Therapeutics, multidrug resistant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 22, 2017 Category: Pharmaceuticals Source Type: news

Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from a Phase 2 study evaluating the safety, efficacy and therapeutic dose range of MK-7264 (formerly AF-219) for the treatment of chronic cough. The highest dose evaluated, 50 mg, reduced Awake Cough Frequency (coughs/hour), the primary endpoint, by 37 percent from baseline relative to placebo (p=0.003). The 50 mg dose also demonstrated a reduction in patient-reported cough severity.Language: EnglishContact: Merc...
Source: Merck.com - Research and Development News - May 22, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK chronic cough MSD NYSE:MRK Source Type: news

Telemedicine Innovator Lemonaid Health Raises $11 Million in Series A Funding
SAN FRANCISCO, May 22, 2017 -- (Healthcare Sales & Marketing Network) -- Lemonaid Health, the simplest and fastest platform for online healthcare, today announced $11 million in new funding to support continued innovation in affordable online healthcare. ... Devices, Venture Capital Lemonaid Health, telemedicine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 22, 2017 Category: Pharmaceuticals Source Type: news

Thermo Fisher Scientific Introduces Latest in Capillary Electrophoresis Technology with new Applied Biosystems(TM) SeqStudio(TM) Genetic Analyzer
New low-throughput Sanger sequencing and fragment analysis platform offers trusted technology and workflow with all-in-one cartridge system and cloud connectivity SOUTH SAN FRANCISCO, Calif., May 22, 2017 -- (Healthcare Sales & Marketing Network) -- Th... Diagnostics, Product Launch Thermo Fisher Scientific, Capillary Electrophoresis, SeqStudio (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 22, 2017 Category: Pharmaceuticals Source Type: news

Bausch and Lomb Introduces renu(R) Advanced Formula Multi-Purpose Solution
New & Improved Formula Builds on Trusted 30-Year Heritage of Meeting Consumers' Lens Care Solution Needs LAVAL, Quebec, May 22, 2017 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wh... Biopharmaceuticals, Ophthalmology, Product Launch Bausch & Lomb, Valeant Pharmaceuticals, renu Advanced Formula (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 22, 2017 Category: Pharmaceuticals Source Type: news

Safety risk for Amgen and UCB’s bone drug lifts rival Radius
Drugmaker’s shares plunge on fears osteoporosis medication will not win approval (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 22, 2017 Category: Pharmaceuticals Source Type: news

10 Ways The Internet of Medical Things Is Revolutionizing Senior Care
In 2000 about 10% of the world ’s population were aged 60 or over. By 2015 that had risen to 12%. United Nations projections indicate that will have increased to 16% by 2030, and jumped to 22% by 2050. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2017 Category: Pharmaceuticals Authors: Reenita Das, Contributor Source Type: news

Reprising The Wrong Verdict For Hormone Replacement At Menopause
Two wrongs about hormone replacement at menopause do not make a right. Lack of use of the right hormones by the right women, like use of the wrong hormones by the wrong women- comes at a cost measured in women's lives. Time to move past summary judgment. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2017 Category: Pharmaceuticals Authors: David L. Katz, Contributor Source Type: news

Amgen's Bone Drug Disappointment Shows Limits Of Genetics In Drug Discovery
Romosozumab for osteoporosis was supposed to be an example of how genetic research can lead to better drugs. Instead, it may increase patients risk of heart attacks -- and may never make it to market. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:AMGN NYSE:SNY NASDAQ:REGN NYSE:MRK Source Type: news

Bluejay Diagnostics' Board Of Directors Announces Appointment Of Douglas C. Wurth As Chairman
ACTON, Mass., May 22, 2017 -- (Healthcare Sales & Marketing Network) -- Bluejay Diagnostics, Inc. (Bluejay) today announced that its board of directors unanimously named Douglas C. Wurth as the Company's chairman, effective immediately. Mr. Wurth rece... Diagnostics, Personnel Bluejay Diagnostics, Allereye, Conjunctivitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 22, 2017 Category: Pharmaceuticals Source Type: news

BONESUPPORT Announces First Patient Enrolled in FORTIFY Trial With CERAMENT G, a Novel Injectable, Antibiotic-eluting Bone Graft Substitute
FORTIFY trial to assess CERAMENT G as part of the surgical repair of severe tibial fractures LUND, Sweden, May 22, 2017 -- (Healthcare Sales & Marketing Network) -- BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute ... Devices, Orthopaedic BONESUPPORT, bioceramic bone substitute, CERAMENT G (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 22, 2017 Category: Pharmaceuticals Source Type: news

Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY(TM) (Romosozumab) In Postmenopausal Women With Osteoporosis
ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures Imbalance in Cardiovascular Events Observed as New Safety Signal THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 -- (... Biopharmaceuticals Amgen, UCB , romosozumab, EVENITY, osteoporosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 22, 2017 Category: Pharmaceuticals Source Type: news

Blame For Obamacare's Next Rate Hike Shifts To Trump And GOP
If cost-sharing subsidies aren ’t funded through 2018, Trump and Republicans will be responsible for more insurers leaving public exchanges and a rate hike of nearly 20 percent on average, reports indicate. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2017 Category: Pharmaceuticals Authors: Bruce Japsen, Contributor Tags: NYSE:ANTM NYSE:CI NYSE:CNC NYSE:THC NYSE:HCA Source Type: news

Don't Give Your Baby Fruit Juice, But A Little For Older Kids Is Okay, Say Pediatricians
Is giving your children juice a bad idea? How much is too much? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2017 Category: Pharmaceuticals Authors: Tara Haelle, Contributor Source Type: news

AstraZeneca enters agreement with Recordati for Seloken in Europe
AstraZeneca announced today that it has entered into an agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK (metoprolol tartrate and metoprolol succinate respectively) and associated Logimax fixed-dose combination (metoprolol succinate and felodipine) treatments in Europe. (Source: World Pharma News)
Source: World Pharma News - May 22, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Medicon Valley Inhalation Consortium (MVIC)-Full Service CRO and Inhalation Product Development Specialists
Medicon Valley Inhalation Consortium (MVIC) offers a comprehensive range of first-class services for the entire value chain of inhalation products, from drug discovery to late-stage development. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 22, 2017 Category: Pharmaceuticals Source Type: news

Novartis receives positive CHMP opinion for first-line use of Zykadia ® in ALK-positive advanced non-small cell lung cancer (NSCLC)
Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of expanding the use of Zykadia® (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive. (Source: World Pharma News)
Source: World Pharma News - May 22, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

UCB shares drop 13% after joint trial with Amgen disappoints
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 22, 2017 Category: Pharmaceuticals Source Type: news

Why Trocaire College is completely overhauling its nursing program
Trocaire College is doing a stem-to-stern overhaul one of its signature programs, with new teaching methods and educational content. The private college in South Buffalo is embracing a "concept-based" model for its nursing program, in which more than 700 students are currently enrolled. Trocaire, like its nursing program competitors in Western New York such as Erie Community College and D'Youville College, has long taught nurs ing through a "medical model." As an example, a class on treating respiratory… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 22, 2017 Category: Pharmaceuticals Authors: Dan Miner Source Type: news

AstraZeneca sells European rights to Seloken heart medicines for over $300m
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 22, 2017 Category: Pharmaceuticals Source Type: news

Video Showing Sea Lion Pulling Young Girl Into Water: Respect The'Wild' In Wild Animals
A video circulating around the internet captures a sea lion at Steveston Fisherman's Wharf in British Columbia snatching a young girl and pulling her into the water off the dock. The girl was not injured, but serves as reminder to maintain a safe distance from wild animals. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 22, 2017 Category: Pharmaceuticals Authors: Robert Glatter, MD, Contributor Source Type: news

Rigaku Analytical Devices to Present Handheld LIBS Analyzer at...
Rigaku KT-100 Katana handheld laser induced breakdown spectroscopy (LIBS) analyzer to be featured at upcoming conferences.(PRWeb May 22, 2017)Read the full story at http://www.prweb.com/releases/2017/05/prweb14356753.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 22, 2017 Category: Pharmaceuticals Source Type: news

Arizona Pain Network Now Offering Insurance Covered Knee Relief with...
The top pain management clinics in Chandler and Scottsdale are now offering cooled radiofrequency ablation of the knee. The nonoperative treatment is covered by insurance and has been extremely...(PRWeb May 22, 2017)Read the full story at http://www.prweb.com/releases/chandler-scottsdale-az/radiofrequency-knee/prweb14348862.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 22, 2017 Category: Pharmaceuticals Source Type: news

Saint Luke ’s Cancer Institute Announces New Clinical Trials...
Affiliation will expand clinical trial access for Saint Luke’s Cancer Institute patients(PRWeb May 22, 2017)Read the full story at http://www.prweb.com/releases/2017/05/prweb14357668.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 22, 2017 Category: Pharmaceuticals Source Type: news

NetDimensions Ranked as a Leader in 2017 Aragon Research Globe ™ for...
NetDimensions has been ranked as a Leader for the third year in a row in the 2017 Aragon Research Globe™ for Corporate Learning.(PRWeb May 22, 2017)Read the full story at http://www.prweb.com/releases/netdimensions-learning/aragon-research/prweb14357531.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 22, 2017 Category: Pharmaceuticals Source Type: news

Bluerock: Canada ’s stem cell contender on the journey from petri dish to clinical trial
Toronto-based regenerative medicine biotech BlueRock Therapeutics was launched in December with a massive $225m series A financing. So what stem cell-based therapies is the company working on? (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Sanofi ’s insulin lispro receives CHMP positive opinion to treat diabetes
The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorisation of Sanofi's insulin lispro. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Merck ’s Isentress receives CHMP positive opinion to treat HIV-1 infection
Merck ’s Isentress (raltegravir) 600mg film-coated tablets have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for the treatment of HIV-1 infection in adults and paedi… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Cancer Research UK funded scientists to test Zika virus on brain tumours
Scientists funded by Cancer Research UK will investigate the effectiveness of the Zika virus in destroying brain tumour cells, which could lead to new treatments for cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Albireo to initiate A4250 ’s Phase III clinical programme to treat PFIC
Albireo Pharma is planning to initiate a Phase III clinical programme of its product candidate A4250 in the second half of this year for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC). (Source: Drug Development Technology)
Source: Drug Development Technology - May 21, 2017 Category: Pharmaceuticals Source Type: news

Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY ™ (Romosozumab) In Postmenopausal Women With Osteoporosis
ARCH Study Met Primary and Key Secondary Endpoints by Reducing the Incidence of New Vertebral, Clinical and Non-Vertebral Fractures Imbalance in Cardiovascular Events Observed as New Safety Signal THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint. At the primary analysis, treatment with EVENITY for 12 months followed by alendronate significantly reduced the incidence of new vertebral fractures through 24 months, clinical f...
Source: Amgen News Release - May 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

' STD-Verified' Dating App Is Startup Culture Via Nutshell: Frank, Unchecked, Inevitable
Now available for iOS, NeatClub is looking to make frequent STI tests part of online dating. However, experts warn that excessive, often inaccurate workups can have high costs for singles, and for society as a whole. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 21, 2017 Category: Pharmaceuticals Authors: Janet Burns, Women at Forbes Source Type: news

IHH leads race to acquire Singh brothers ’ healthcare operations
IHH is competing with a private equity consortium of TPG and General Atlantic to acquire controlling stakes in both Fortis Healthcare and Fortis Malhar. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 21, 2017 Category: Pharmaceuticals Source Type: news

The challenge that awaits a new leader of the WHO
Without refocusing the global health agency, its vital role will dwindle (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 21, 2017 Category: Pharmaceuticals Source Type: news

Here Are The Next Steps To Tackling The Opioid Epidemic
Gary Mendell and Shatterproof are implementing a plan...and it's got lots of science. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 21, 2017 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news